Our study highlights CTSZ as a potential prognostic and therapeutic biomarker in PCa, demonstrating that its overexpression is associated with immune cell infiltration, immune checkpoint molecule expression (such as PD-1 and PD-L1), tumor mutation burden, and key oncogenic pathways. This evidence concerns the gene CTSZ and neoplasm.